Shilpa Gupta, MD

Dr. Shilpa Gupta is the Director of the Genitourinary Medical Oncology at TCI and Co-Leader of the Genitourinary Oncology Program at Cleveland Clinic.

Dr. Gupta obtained her Medical Degree at the Lady Hardinge Medical College in New Delhi, India and completed a residency in Internal Medicine at the University of Connecticut Health Center. She completed Hematology-Oncology fellowship at Georgetown University and Thomas Jefferson University followed by a Genitourinary Oncology Translational Research fellowship at Thomas Jefferson University. Dr. Gupta was a faculty at H. Lee Moffitt Cancer Center and Research Institute in Tampa, Florida in the Departments of Genitourinary Oncology and Experimental Therapeutics from 2011 until 2015. From 2015 until 2019, she was Associate Professor and Lead for the Solid Tumor Phase 1 Program at Masonic Cancer Center, University of Minnesota. Dr. Gupta serves on the ASCO Annual Scientific Committee for Genitourinary Cancers and SITC Anti-PD-1/PD-L1 Resistance Task Force. She serves on the panel of the SITC Cancer Immunotherapy Guidelines, International Bladder Cancer Group core committee and Society of International Urology Innovators. She also serves on the Steering Committee and Scientific Advisory Board for the Bladder Cancer Advocacy Network.

Dr. Gupta’s research interests are novel drug development and understanding biomarkers of response and resistance to therapies in bladder cancer.  Dr. Gupta has led several Investigator Initiated Trials in Genitourinary Cancers and has leadership roles in several NCI trials. She is the Study Chair for A032001 MAIN-CAV, a Phase III Randomized Trial of Maintenance Cabozantinib and Avelumab vs Maintenance Avelumab After First-Line Platinum-Based Chemotherapy in Patients with Metastatic Urothelial Cancer.

She is Principal Investigator of 2020 Department of Defense Idea Award to study the biomarkers of response and resistance to immunotherapy in bladder cancer and Co-Principal Investigator of Department of Defense Team Translational Science Award to study immunotherapy combination strategies to overcome resistance in bladder cancer. Dr. Gupta is the Co-Chair of the Hoosier Cancer Research Network (HCRN) Genitourinary Working Group and Co-Chair of the Case Comprehensive Cancer Center PRMC committee.

Her research work has been published in peer-reviewed journals including the Journal of Clinical oncology, Lancet Oncology, Clinical Cancer Research, European oncology, among others. She is the author for the AUA core curriculum for penile cancer and serves on the NCCN Guidelines Panel for Prostate Cancer.

Dr. Gupta  is active in several professional organizations including the American Society of Clinical Oncology (ASCO), American Urologic Association (AUA), American Association of Cancer Research (AACR), Society of Urologic Oncology (SUO), Society of Immunotherapy for cancer (SITC), Prostate Cancer Foundation (PCF) and the European Society of Medical Oncology (ESMO).

“I wanted to become an active member of BCAN to learn and promote science and research to offer ‘patient-centric’ care for our bladder cancer patients.” – Dr. Gupta